Introduction to Pharmacovigilance
Pharmacovigilance (PV) is the science and practice of identifying, analyzing, comprehending, and preventing side effects or other drug-related issues (Bate, 2019). In a pharmaceutical world characterized by rapid innovation and international marketplaces, safeguarding medication safety beyond commercialization has never been more important. Regulatory agencies throughout the world have built tough PV frameworks to guarantee that once a product has been authorized, it is rigorously monitored (Biomapas, n.d.). Effective pharmacovigilance is critical not just for meeting regulatory obligations, but also for protecting patients and maintaining trust in healthcare systems.
Regulatory Landscape
Global Harmonization Efforts
Modern pharmacovigilance rules are based on the International Council for Harmonisation (ICH) recommendations, namely ICH E2E (Pharmacovigilance Planning) and ICH E2D (Post-Approval Safety Data Management) (CDER, 2018) (CDER, 2024c). These frameworks help businesses build risk management strategies and report unfavorable occurrences efficiently. Regulatory bodies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) have accepted ICH principles, although regional disparities remain.
For example, the EMA requires the use of EudraVigilance for electronic reporting of suspected adverse events, but the FDA requires submission via the FDA Adverse Event Reporting System (FAERS) database (EMA, 2013) (CDER, 2024a). In low- and middle-income nations, WHO's Programme for International Drug Monitoring and its worldwide database VigiBase, which is administered by the Uppsala Monitoring Centre, are crucial (UMC, n.d.).
South Korea’s Ministry of Food and Drug Safety (MFDS) is responsible for PV, but has not explicitly accepted ICH recommendations. Likewise, it is not entirely clear whether China’s National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) strictly follow the IHC in their PV efforts.
Risk Management Plans (RMPs) and REMS
Regulators may demand Risk Management Plans (EU) or Risk Evaluation and Mitigation Strategies (REMS in the US) as part of the medication approval process (EMA, 2006) (CDER, 2023). These frameworks proactively evaluate safety signals and require risk-reduction measures such as regulated distribution programs, instructional materials for healthcare professionals, and post-marketing clinical trials.
Application of Pharmacovigilance in Practice
Spontaneous Reporting and Signal Detection
Spontaneous reporting is a key component of PV. Healthcare personnel and patients report suspected adverse drug reactions (ADRs), which are subsequently entered into safety databases. With hundreds of complaints filed worldwide, signal identification algorithms, ranging from disproportionality analysis to Bayesian methods, are utilized to identify possible safety problems that require additional examination (Liu, 2024).
However, spontaneous reports are frequently characterized by underreporting, duplication, and a lack of causation information. As a result, more complex techniques using real-world data are being introduced to supplement existing systems.
Real-World Evidence (RWE)
To counter the limits of spontaneous reporting, authorities are increasingly relying on real-world information gathered from electronic health records, insurance claims, patient registries, and social media data. This larger viewpoint aids in the identification of long-term or unusual side effects that were not observed in clinical studies. The FDA's Sentinel Initiative and the EU's DARWIN EU network are important projects that provide proactive safety monitoring with real-world data (CDER, 2024b) (EMA, 2025).
Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs)
Marketing Authorization Holders (MAHs) are required to submit Periodic Safety Update Reports (PSURs) or Periodic Benefit-Risk Evaluation Reports (PBRERs) at certain intervals following ap...
(All Rights Reserved)